6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 07 Apr 2026
- Reporting date
- 07 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,784 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 76-100 of 1,000 matching filings.
Per page
25
Current page
4
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 02 Apr 2026
- Reporting date
- 02 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 01 Apr 2026
- Reporting date
- 01 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TOTAL VOTING RIGHTS
- Filing date
- 01 Apr 2026
- Reporting date
- 01 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 01 Apr 2026
- Reporting date
- 01 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING
- Filing date
- 01 Apr 2026
- Reporting date
- 01 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 31 Mar 2026
- Reporting date
- 31 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA
- Filing date
- 30 Mar 2026
- Reporting date
- 30 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA
- Filing date
- 30 Mar 2026
- Reporting date
- 30 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 30 Mar 2026
- Reporting date
- 30 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 27 Mar 2026
- Reporting date
- 27 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA
- Filing date
- 27 Mar 2026
- Reporting date
- 27 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 26 Mar 2026
- Reporting date
- 26 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 25 Mar 2026
- Reporting date
- 25 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
NOTICE OF AGM
- Filing date
- 25 Mar 2026
- Reporting date
- 25 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 25 Mar 2026
- Reporting date
- 25 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 24 Mar 2026
- Reporting date
- 24 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 23 Mar 2026
- Reporting date
- 23 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
ADMISSION TO TRADING
- Filing date
- 23 Mar 2026
- Reporting date
- 23 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS
- Filing date
- 23 Mar 2026
- Reporting date
- 23 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 23 Mar 2026
- Reporting date
- 23 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 20 Mar 2026
- Reporting date
- 20 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
LYNAVOY (LINERIXIBAT) APPROVED BY US FDA
- Filing date
- 19 Mar 2026
- Reporting date
- 19 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 19 Mar 2026
- Reporting date
- 19 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 18 Mar 2026
- Reporting date
- 18 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing